NEUROONE MEDICAL TECHNOLOGIES Corp Annual Report - How They Did This Year (Fiscal Year Ended September 30, 2025)

Hey there, fellow investor! Let's dive into NeuroOne Medical Technologies Corp's performance for their fiscal year, which wrapped up on September 30, 2025.

Who is NeuroOne Medical Technologies Corp? NeuroOne Medical Technologies Corporation, or "NeuroOne" as we'll call them, trades on The Nasdaq Stock Market LLC under the ticker symbol NMTC. They're considered a "smaller reporting company" and a "non-accelerated filer." This means they are a smaller public company, which often comes with different reporting requirements compared to giant corporations. This status can sometimes mean more growth potential, but also potentially higher risks.

A Quick Look at Their Size As of March 31, 2025, the total value of their common stock available to the public (not held by insiders) was about $25.5 million. They had 50,413,148 shares of common stock outstanding as of December 12, 2025.

What's on Their Mind for the Future? (Their Game Plan & What to Watch Out For) NeuroOne is looking ahead, and they've shared a lot about what they're focusing on and what could impact their journey. Think of these as their main goals and the challenges they're keeping an eye on:

• Getting Products to Market: A big focus is successfully selling their technology in the United States.
• Partnerships are Key: They're working closely with companies like Zimmer, Inc. and are open to other collaborations to develop and distribute their products.
• Product Performance: Ensuring their products work well and are reliable is crucial.
• Regulatory Hurdles: They need to maintain approvals for their products and technology from regulatory bodies.
• Becoming Profitable: A major goal is to start making and sustaining a profit.
• Funding Their Growth: They'll need to raise more money to keep their operations going and grow the business.
• Innovation: Developing new and improved versions of their technology, like their cortical strip, grid, and depth electrode technology, is a priority.
• Manufacturing: They rely on third-party manufacturers, so ensuring these partners are performing well and meeting regulations is important.
• Getting Paid: They're working on getting more insurance coverage (reimbursement) for their technology, which helps patients and hospitals afford their products.
• Doctor Adoption: Getting healthcare providers to recommend their technology to patients is key for sales.
• Global Ambitions: They're exploring opportunities to sell their products internationally.
• Market Growth: They're estimating the potential size and growth of the market for their current and future technologies.

These points highlight both their strategic direction and the potential risks or uncertainties that could affect their success.

---

Key Takeaways for Investors:

Based on the information provided, NeuroOne Medical Technologies Corp (NMTC) is a smaller public company focused on medical technology. As of late 2025, the company had a public float of $25.5 million and over 50 million shares outstanding. Their strategic priorities include commercializing products in the U.S., leveraging partnerships (such as with Zimmer, Inc.), ensuring product reliability, navigating regulatory requirements, achieving profitability, securing funding, and innovating their electrode technology. They are also focused on managing third-party manufacturing, improving reimbursement for their products, driving adoption by healthcare providers, and exploring international market opportunities.